Biofrontera Inc.

Welcome to the BioFrontera, Inc. second quarter 2022 financial results and business update conference call. At this time, all participants are in listen-only mode. Should you need assistance, please schedule a conference specialist by pressing the star key followed by zero. After today's prepared remarks, there will be an opportunity to ask questions. To ask a question, please press star then one on your telephone keypad. To withdraw a question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Terence Patel with LHA Investor Relations. Please go ahead.

Good morning, and welcome to BioFrontera, Inc.' 's second quarter 2022 Financial Results and Business Update conference call. Please note that certain information discussed during today's call by management is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that BioFrontera's management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in BioFrontier's press releases and SEC filings. Also, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast today, August 12, 2022. BioFrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non-GAAP financial measures. BioFrontera believes these measures provide useful information for investors, yet should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in this morning's press release. More specifically, management will be referencing adjusted EBITDA, a non-GAAP financial measure defined as net income or loss, excluding interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items. With that, I would like to turn the call over to Herman Loubert, Executive Chairman of BioFrontier, Inc.

Thank you, Thomas. and welcome everyone to BioFrontera Inc's second quarter conference call. Joining me today is Erika Monaco, our Chief Executive Officer. In a moment, Erika will review the business or strategy of our recent financial results. But first, I would like to say a few words. I'm proud of the entire BioFrontera team and the hard work to generate such strong first half financial results following a foundational year that included our successful IPO. In view of these results, I view these results as validation of the data-driven approach we initiated about a year ago that equips our sales force with valuable information to enhance their success. Of note, BioFrontera was recently named by CIO coverage magazine as one of the 10 fastest-growing life sciences companies to watch in 2022, and we believe the results of our execution here today certainly support that recognition. Adoption of photodynamic therapy is growing, as are the clinical successes among BioFrontera-sponsored and investigator-initiated clinical studies using our products. These studies boost our efforts as we establish BioFrontera as a market-leading brand in dermatology. To our licensor, we have several ongoing clinical studies with Amelus, and I am certain that we will be able to provide positive news on ongoing and new clinical trials and the underlying patent protection in the coming months. With that, I'll turn the call over to Erika.